Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.

PloS one - 1 Jan 2012

Matulis Shannon M, Morales Alejo A, Yehiayan Lucy, Lee Kelvin P, Cai Yong, Boise Lawrence H

Abstract excerpt

Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success. In order to better understand drug mechanism and resistance pathways in myeloma we generated an ATO-resistant cell line, 8226/S-ATOR05, with an IC50 that is 2-3-fold higher than control cell lines and significantly higher than clinically achievable concentrations. Interestingly we found two parallel pathways...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Arsenicals

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Doxorubicin

Share to Glutathione

Share to Melphalan

Share to Minor Histocompatibility Antigens

Share to Multiple Myeloma

Share to Oxides

Source

Open in PubMed Open full text

Identifiers

PMID: 23285138
DOI: 10.1371/journal.pone.0052662
PMCID: PMC3528737

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.PMID 23285138Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

Arsenic trioxide resistance in acute promyelocytic leukemia: More to it than PML mutationsSemantic proximity Read ↗

Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.Semantic proximity Read ↗

Arsenic-Based Antineoplastic Drugs and Their Mechanisms of ActionSemantic proximity Read ↗

Metabolic adaptation drives arsenic trioxide resistance in acute promyelocytic leukemiaSemantic proximity Read ↗

Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2Semantic proximity Read ↗

Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.Semantic proximity Read ↗

Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53.Semantic proximity Read ↗

Characterization of a R115777-resistant human multiple myeloma cell line with cross-resistance to PS-341.Semantic proximity Read ↗

Dual effects of arsenic trioxide (As2O3) on non‐acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferationSemantic proximity Read ↗

Inhibition of NRF2 signaling overcomes acquired resistance to arsenic trioxide in FLT3-mutated Acute Myeloid Leukemia.Semantic proximity Read ↗

Selection for Drug Resistance Results in Resistance to Fas-Mediated ApoptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.